JP2023504744A5 - - Google Patents

Info

Publication number
JP2023504744A5
JP2023504744A5 JP2022534195A JP2022534195A JP2023504744A5 JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5 JP 2022534195 A JP2022534195 A JP 2022534195A JP 2022534195 A JP2022534195 A JP 2022534195A JP 2023504744 A5 JP2023504744 A5 JP 2023504744A5
Authority
JP
Japan
Prior art keywords
sequence
seq
rnai construct
construct according
sequence number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022534195A
Other languages
English (en)
Japanese (ja)
Other versions
JP7827623B2 (ja
JP2023504744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063844 external-priority patent/WO2021119034A1/en
Publication of JP2023504744A publication Critical patent/JP2023504744A/ja
Publication of JP2023504744A5 publication Critical patent/JP2023504744A5/ja
Priority to JP2026028952A priority Critical patent/JP2026122489A/ja
Application granted granted Critical
Publication of JP7827623B2 publication Critical patent/JP7827623B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022534195A 2019-12-09 2020-12-08 LPA発現を阻害するためのRNAiコンストラクト及び方法 Active JP7827623B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026028952A JP2026122489A (ja) 2019-12-09 2026-02-25 LPA発現を阻害するためのRNAiコンストラクト及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962945777P 2019-12-09 2019-12-09
US62/945,777 2019-12-09
PCT/US2020/063844 WO2021119034A1 (en) 2019-12-09 2020-12-08 RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026028952A Division JP2026122489A (ja) 2019-12-09 2026-02-25 LPA発現を阻害するためのRNAiコンストラクト及び方法

Publications (3)

Publication Number Publication Date
JP2023504744A JP2023504744A (ja) 2023-02-06
JP2023504744A5 true JP2023504744A5 (cg-RX-API-DMAC7.html) 2023-12-13
JP7827623B2 JP7827623B2 (ja) 2026-03-10

Family

ID=74141837

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022534195A Active JP7827623B2 (ja) 2019-12-09 2020-12-08 LPA発現を阻害するためのRNAiコンストラクト及び方法
JP2026028952A Pending JP2026122489A (ja) 2019-12-09 2026-02-25 LPA発現を阻害するためのRNAiコンストラクト及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026028952A Pending JP2026122489A (ja) 2019-12-09 2026-02-25 LPA発現を阻害するためのRNAiコンストラクト及び方法

Country Status (7)

Country Link
US (1) US20230078200A1 (cg-RX-API-DMAC7.html)
EP (1) EP4073252A1 (cg-RX-API-DMAC7.html)
JP (2) JP7827623B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020399636A1 (cg-RX-API-DMAC7.html)
CA (1) CA3163322A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007005A (cg-RX-API-DMAC7.html)
WO (1) WO2021119034A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250077604A (ko) * 2020-08-05 2025-05-30 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
WO2022121959A1 (zh) * 2020-12-09 2022-06-16 纳肽得有限公司 siRNA分子及其在治疗冠状动脉疾病中的应用
US20250283076A1 (en) * 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041079A1 (zh) * 2021-09-18 2023-03-23 上海金中锘美生物医药科技有限公司 Lpa抑制剂及其用途
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
TW202345865A (zh) * 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
KR20250043473A (ko) * 2022-07-27 2025-03-28 이-테라퓨틱스 피엘씨 핵산 화합물
WO2024081954A2 (en) * 2022-10-14 2024-04-18 Sanegene Bio Usa Inc. Small interfering rna targeting c3 and uses thereof
TW202440921A (zh) * 2022-12-05 2024-10-16 美商美國禮來大藥廠 經修飾之寡核苷酸
CN121294438A (zh) * 2022-12-19 2026-01-09 昂拓生物医药有限公司 高级rna靶向(arnatar)
WO2024138111A1 (en) * 2022-12-23 2024-06-27 Eli Lilly And Company Novel rna therapeutics and uses thereof
US20260209772A1 (en) * 2022-12-23 2026-07-23 Eli Lilly And Company Novel rna therapeutics and uses thereof
CN119384503A (zh) * 2023-04-03 2025-01-28 翰森(上海)健康科技有限公司 靶向LPA基因的RNAi剂及其用途
WO2024222686A1 (zh) * 2023-04-24 2024-10-31 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
JP2026520116A (ja) * 2023-05-11 2026-06-22 大睿生物 MASP2遺伝子活性を制御するためのdsRNA分子
CN118685405A (zh) * 2023-06-20 2024-09-24 施能康医药科技(苏州)有限公司 靶向脂蛋白a的核酸及其用途
EP4741502A1 (en) 2023-07-04 2026-05-13 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Dsrna molecule for inhibiting lp(a) gene expression and use thereof
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA,含其的組合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN117805370B (zh) * 2023-12-29 2025-11-04 深圳市新产业生物医学工程股份有限公司 胶乳免疫比浊的检测试剂、试剂盒及检测方法
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe
WO2026026812A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用
WO2026026811A1 (zh) * 2024-07-29 2026-02-05 成都先衍生物技术有限公司 一种具有双靶点基因抑制作用的核酸缀合物及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5840710A (en) 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US8017762B2 (en) 2003-04-17 2011-09-13 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
EP2669377A3 (en) 2003-04-17 2015-10-14 Alnylam Pharmaceuticals Inc. Modified iRNA agents
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
US7723509B2 (en) 2003-04-17 2010-05-25 Alnylam Pharmaceuticals IRNA agents with biocleavable tethers
WO2008131419A2 (en) 2007-04-23 2008-10-30 Alnylam Pharmaceuticals, Inc. Glycoconjugates of rna interference agents
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
WO2014205451A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
JOP20160211B1 (ar) * 2015-10-01 2021-08-17 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
AR113490A1 (es) * 2017-12-12 2020-05-06 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
SG11202105900UA (en) * 2018-12-10 2021-07-29 Amgen Inc CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2023537943A5 (cg-RX-API-DMAC7.html)
JP2022511866A5 (cg-RX-API-DMAC7.html)
JP2021521796A5 (cg-RX-API-DMAC7.html)
TWI784934B (zh) 抑制lpa之基因表現之組合物及方法
JP2019214587A5 (cg-RX-API-DMAC7.html)
JP2023103244A5 (cg-RX-API-DMAC7.html)
JP6060178B2 (ja) 高効率のナノ粒子型二本鎖オリゴrna構造体およびその製造方法
JP2021006029A5 (cg-RX-API-DMAC7.html)
JP2024105284A5 (cg-RX-API-DMAC7.html)
JP2019122379A (ja) 細胞内貫通能を持ってrna干渉を誘導する核酸分子およびその用途
JP2011511636A5 (cg-RX-API-DMAC7.html)
JP2026077722A (ja) Dux4阻害剤およびその使用方法
CN118440938B (zh) 一种靶向AGT基因表达的siRNA及其缀合物和用途
JP2009514877A5 (cg-RX-API-DMAC7.html)
JP2008527993A (ja) 特異性及び送達の改善のためのsiRNA分子、shRNA分子又はアンチセンス分子及び機能的実体を含む複合体
JP2022511550A5 (cg-RX-API-DMAC7.html)
IL323761A (en) Dual silencing
JP2020529197A5 (cg-RX-API-DMAC7.html)
JP2025522282A (ja) オレイン酸にコンジュゲートしたオリゴヌクレオチド及びその使用
JP2026500220A (ja) 高度rna標的化(arnatar)
WO2024163497A2 (en) Products and compositions
CN121152879A (zh) 经修饰的双链rna药剂
JP2024537098A5 (cg-RX-API-DMAC7.html)
AU2019271311B2 (en) Methods for treating VEGF-related conditions
WO2024164008A1 (en) Products and compositions